Florida Financial Advisors LLC Increases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Florida Financial Advisors LLC grew its stake in United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 822 shares of the biotechnology company’s stock after acquiring an additional 48 shares during the period. Florida Financial Advisors LLC’s holdings in United Therapeutics were worth $290,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $25,000. Brooklyn Investment Group purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at $33,000. Millstone Evans Group LLC purchased a new position in United Therapeutics during the 4th quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its stake in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 258 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $919,164.36. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,755 shares of company stock valued at $29,792,021 in the last three months. 11.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Stock Down 1.0 %

Shares of UTHR opened at $316.73 on Wednesday. United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The stock has a 50 day moving average price of $343.28 and a 200 day moving average price of $356.63. The company has a market capitalization of $14.22 billion, a price-to-earnings ratio of 13.91, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period last year, the firm posted $4.36 EPS. On average, equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.